MacroGenics, Inc. — Q1 2016 Form 10-Q
Business context and period: Biopharmaceutical company developing antibody-based therapies for cancer, autoimmune disorders and infectious diseases. The filing covers the three months ended March 31, 2016; financial statements are unaudited. MacroGenics had no product-sales revenue. Management reported an accumulated deficit of $264.5 million.
Key financial results
| Metric | Q1 2016 | Q1 2015 |
|---|---|---|
| Total revenue | $2.8 million | $71.3 million |
| Research and development expense | $27.3 million | $21.5 million |
| General and administrative expense | $6.1 million | $4.7 million |
| Operating income (loss) | $(30.6) million | $45.1 million |
| Net income (loss) | $(30.4) million | $45.1 million |
| Basic and diluted EPS | $(0.88) | $1.53 basic; $1.42 diluted |
| Operating cash flow | $(31.9) million | $43.6 million |
Revenue and operating margins are not directly comparable as Q1 2015 included substantial collaboration revenue recognized under Janssen; the filing does not report a gross margin. Cash, cash equivalents and marketable securities totaled $304.4 million at March 31, 2016, versus $339.0 million at December 31, 2015. Cash and cash equivalents alone were $152.0 million. Current assets were $309.3 million and current liabilities $17.8 million. No interest-bearing debt is disclosed.
Cash declined by $44.2 million during the quarter. Investing activities used $12.5 million, principally reflecting purchases of marketable securities and facility improvements; financing provided $0.2 million, mainly from stock-option exercises. The investment portfolio consisted of short-term securities, all with maturities under one year.
Material changes versus Q1 2015
- Revenue fell $68.5 million, or 96%, primarily because Q1 2015 included $62.3 million recognized under Janssen after MacroGenics met its performance obligation; lower Boehringer and Takeda revenue also contributed.
- R&D expense rose $5.8 million, or 27%, driven mainly by preclinical immune-checkpoint programs and initiation of two Phase 1 combination trials involving enoblituzumab. G&A expense increased $1.4 million, or 30%, primarily from labor-related costs, including stock compensation.
- The period shifted from net income and positive operating cash flow to a net loss and operating cash outflow. Q1 2015 financing cash flow included $62.7 million of net proceeds from the JJDC stock investment; Q1 2016 did not.
- Takeda-related MGD010 option-fee revenue recognition was prospectively extended by eight months after the company revised its expected development period.
Outlook, risks and notable items
- Management expects cash, cash equivalents, investments and anticipated collaboration receipts to fund operations into 2018, assuming programs advance as currently contemplated. This runway depends partly on uncertain collaboration payments and milestones.
- The company expects operating expenses to increase as clinical trials and preclinical development continue. It has no product-sales revenue and states that approval and commercialization timing is uncertain.
- Potential collaboration economics include milestone payments, royalties and options, but depend on successful development, regulatory approval, commercialization and/or collaborators exercising options. Janssen leads MGD011 development; Takeda retains an MGD010 option; Servier has exercised its MGD006 option.
- A NIAID contract provides a $7.5 million base period and up to $17.0 million in additional option funding for development of up to two DART molecules. The company recognized $0.9 million of contract revenue in Q1 2016.
- Raven acquisition-related contingent payments could arise upon specified clinical or sales milestones; no additional amounts were recorded in the quarter. The lease-exit liability was $4.2 million at quarter-end.
- The company adopted deferred-tax classification guidance prospectively, reclassifying $0.7 million of current deferred tax liabilities to noncurrent, with no effect on results or cash flows. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
- Key risks include clinical-trial outcomes and timing, regulatory approvals, financing needs, collaboration milestones and funding, competition, intellectual-property protection, litigation, and the ability to commercialize candidates. The filing refers readers to the 2015 Form 10-K risk factors.
Important facts for investors to verify
- Whether the stated runway into 2018 remains supported by actual cash burn and collaboration receipts, and how sensitive it is to program timing or milestone assumptions.
- Progress, costs and clinical results for major programs, including margetuximab, enoblituzumab, MGD006, MGD010 and MGD011.
- Whether Takeda exercises the MGD010 option and whether other collaborators advance programs, trigger milestones or provide expected funding.
- The recurring level of operating expenses and cash use after excluding the unusually large Q1 2015 Janssen revenue recognition.
- Potential future contingent obligations, including Raven-related payments, and the timing and amount of deferred collaboration revenue recognition.